Phenotype
|
Fish
|
Conditions
|
Figures
|
whole organism decreased mobility, abnormal
|
AB + MO3-spast
|
standard conditions
|
Fig. 8
from Allison et al., 2013
|
spinal cord motor neuron truncated, abnormal
|
AB + MO3-spast
|
standard conditions
|
Fig. 8
from Allison et al., 2013
|
axon extension disrupted, abnormal
|
AB + MO3-spast
|
standard conditions
|
Fig. 8
from Allison et al., 2013
|
spinal cord motor neuron branchiness, abnormal
|
AB + MO3-spast
|
standard conditions
|
Fig. 8
from Allison et al., 2013
|
whole organism increased curvature, abnormal
|
AB + MO3-spast
|
standard conditions
|
Fig. 8
from Allison et al., 2013
|
whole organism arched, abnormal
|
WT + MO3-spast
|
standard conditions
|
Fig. 9
from Julien et al., 2016
|
secondary motor neuron axon guidance process quality, abnormal
|
WT + MO3-spast
|
control
|
Fig. 6
from Jardin et al., 2018
|
head hydrocephalic, ameliorated
|
WT + MO3-spast
|
chemical treatment: phenazine
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton organization disrupted, ameliorated
|
WT + MO3-spast
|
chemical treatment: phenazine
|
Fig. 9
from Julien et al., 2016
|
whole organism arched, ameliorated
|
WT + MO3-spast
|
chemical treatment: phenazine
|
Fig. 9
from Julien et al., 2016
|
extension morphology, ameliorated
|
WT + MO3-spast
|
chemical treatment: methylene blue
|
Fig. 9
from Julien et al., 2016
|
head hydrocephalic, ameliorated
|
WT + MO3-spast
|
chemical treatment: methylene blue
|
Fig. 9
from Julien et al., 2016
|
head hydrocephalic, ameliorated
|
WT + MO3-spast
|
chemical treatment: Guanabenz
|
Fig. 9
from Julien et al., 2016
|
reactive oxygen species metabolic process process quality, ameliorated
|
WT + MO3-spast
|
chemical treatment: salubrinal
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton organization disrupted, ameliorated
|
WT + MO3-spast
|
chemical treatment: methylene blue
|
Fig. 9
from Julien et al., 2016
|
caudal fin curved, abnormal
|
WT + MO3-spast
|
control
|
Fig. 2
from Jardin et al., 2018
|
motor neuron axon microtubule bundle decreased diameter, abnormal
|
WT + MO3-spast
|
standard conditions
|
Fig. 9
from Julien et al., 2016
|
extension morphology, ameliorated
|
WT + MO3-spast
|
chemical treatment: salubrinal
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton organization disrupted, ameliorated
|
WT + MO3-spast
|
chemical treatment: Guanabenz
|
Fig. 9
from Julien et al., 2016
|
reactive oxygen species metabolic process process quality, abnormal
|
WT + MO3-spast
|
standard conditions
|
Fig. 9
from Julien et al., 2016
|
reactive oxygen species metabolic process process quality, ameliorated
|
WT + MO3-spast
|
chemical treatment: Guanabenz
|
Fig. 9
from Julien et al., 2016
|
head hydrocephalic, abnormal
|
WT + MO3-spast
|
standard conditions
|
Fig. 9
from Julien et al., 2016
|
motor neuron axon microtubule bundle decreased diameter, ameliorated
|
WT + MO3-spast
|
chemical treatment: phenazine
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton organization disrupted, abnormal
|
WT + MO3-spast
|
standard conditions
|
Fig. 9
from Julien et al., 2016
|
reactive oxygen species metabolic process process quality, ameliorated
|
WT + MO3-spast
|
chemical treatment: phenazine
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton disorganized, ameliorated
|
WT + MO3-spast
|
chemical treatment: Guanabenz
|
Fig. 9
from Julien et al., 2016
|
extension morphology, ameliorated
|
WT + MO3-spast
|
chemical treatment: Guanabenz
|
Fig. 9
from Julien et al., 2016
|
motor neuron axon microtubule bundle decreased diameter, ameliorated
|
WT + MO3-spast
|
chemical treatment: Guanabenz
|
Fig. 9
from Julien et al., 2016
|
motor neuron axon microtubule bundle decreased diameter, ameliorated
|
WT + MO3-spast
|
chemical treatment: salubrinal
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton disorganized, ameliorated
|
WT + MO3-spast
|
chemical treatment: methylene blue
|
Fig. 9
from Julien et al., 2016
|
whole organism arched, ameliorated
|
WT + MO3-spast
|
chemical treatment: methylene blue
|
Fig. 9
from Julien et al., 2016
|
whole organism arched, ameliorated
|
WT + MO3-spast
|
chemical treatment: salubrinal
|
Fig. 9
from Julien et al., 2016
|
extension morphology, ameliorated
|
WT + MO3-spast
|
chemical treatment: phenazine
|
Fig. 9
from Julien et al., 2016
|
thigmotaxis process quality, abnormal
|
WT + MO3-spast
|
control
|
Fig. 2
from Jardin et al., 2018
|
whole organism arched, ameliorated
|
WT + MO3-spast
|
chemical treatment: Guanabenz
|
Fig. 9
from Julien et al., 2016
|
extension morphology, abnormal
|
WT + MO3-spast
|
standard conditions
|
Fig. 9
from Julien et al., 2016
|
motor neuron axon microtubule bundle decreased diameter, ameliorated
|
WT + MO3-spast
|
chemical treatment: methylene blue
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton disorganized, ameliorated
|
WT + MO3-spast
|
chemical treatment: salubrinal
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton disorganized, abnormal
|
WT + MO3-spast
|
standard conditions
|
Fig. 9
from Julien et al., 2016
|
head hydrocephalic, ameliorated
|
WT + MO3-spast
|
chemical treatment: salubrinal
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton disorganized, ameliorated
|
WT + MO3-spast
|
chemical treatment: phenazine
|
Fig. 9
from Julien et al., 2016
|
spinal cord microtubule cytoskeleton organization disrupted, ameliorated
|
WT + MO3-spast
|
chemical treatment: salubrinal
|
Fig. 9
from Julien et al., 2016
|
reactive oxygen species metabolic process process quality, ameliorated
|
WT + MO3-spast
|
chemical treatment: methylene blue
|
Fig. 9
from Julien et al., 2016
|
secondary motor neuron axon guidance process quality, abnormal
|
ml2Tg + MO3-spast
|
control
|
Fig. 3
from Jardin et al., 2018
|
secondary motor neuron axon guidance process quality, abnormal
|
w30Tg + MO3-spast
|
control
|
Fig. 6
from Jardin et al., 2018
|
secondary motor neuron axon guidance process quality, ameliorated
|
w30Tg + MO3-spast
|
heat shock
|
Fig. 6
from Jardin et al., 2018
|
secondary motor neuron axon guidance process quality, exacerbated
|
ml2Tg + MO1-atl1 + MO3-spast
|
control
|
Fig. 6
from Jardin et al., 2018
|